©2024 Stanford Medicine
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Not Recruiting
Trial ID: NCT01617954
Purpose
This is a prospective study that will assess the impact of MammaPrint on chemotherapy +
endocrine versus endocrine alone treatment decisions in patients with an Oncotype
Intermediate Score.
Official Title
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Stanford Investigator(s)
Mark Pegram
Susy Yuan-Huey Hung Professor
Eligibility
Inclusion Criteria:
- Women with histologically proven invasive stage I-II, node negative, hormone receptor
positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score
(18-30)
- ≥ 18 years of age at time of consent
- Written informed consent
Exclusion Criteria:
- Insufficient tissue remaining for Mammaprint FFPE
- Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
- Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy
Intervention(s):
device: MammaPrint
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Annabel Castaneda
650-498-7977